Does intravenous eptinezumab help reduce pain during an ongoing episodic migraine attack?
Eptinezumab is an intravenous medication approved for preventing episodic migraine. While it is primarily a preventive treatment, real-world studies show it can also help stop pain during an active attack. Research indicates that pain levels drop significantly within the first 10 to 20 minutes after the infusion starts.
What the research says
Other research compares eptinezumab to other migraine prevention drugs. In a large analysis of different CGRP therapies, eptinezumab ranked highest for reducing the number of monthly migraine days 1. However, the specific ability to stop pain during an active attack is best supported by the real-world infusion data described above 25.
What to ask your doctor
- Can I use intravenous eptinezumab to treat a migraine attack that is already happening?
- How quickly do I usually feel pain relief after the infusion starts?
- Are there specific symptoms like light sensitivity that improve faster than the pain itself?
- Is this treatment covered by my insurance when used for an active attack versus prevention?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.